GlassScriptPhysician profile
Danielle P Waldron
NPI 1851724223
$4,050.24
in general payments reported to CMS, 2019-2025
19 companies · $893 in 2025
The $893 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $617 · 2023: $633 · 2024: $1,024 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $694.61 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $481.43 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $369.24 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.56 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $328.05 | 2023-2025 | Auvelity |
| Corium, LLC | $311.77 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $258.32 | 2024-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $205.28 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $162.39 | 2022-2024 | Lybalvi |
| Tris Pharma INC | $151.12 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $145.36 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $132.23 | 2022-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $127.11 | 2021-2025 | Spravato |
| Neurocrine Biosciences, INC. | $109.55 | 2021 | |
| Biogen, INC. | $80.33 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $49.89 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $38.20 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $27.29 | 2024 | |
| Allergan, INC. | $23.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Waldron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.